Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
“We are delighted that our research on phenethylamine serotonin 5-HT2 receptor agonists was published in this important journal,” said Doug Drysdale, Chief Executive Officer of Cybin.
- “We are delighted that our research on phenethylamine serotonin 5-HT2 receptor agonists was published in this important journal,” said Doug Drysdale, Chief Executive Officer of Cybin.
- “This study is an example of our expanding scope of innovative development work beyond our clinical tryptamine programs.
- This research led to the discovery of CYB210010, a potent and long-acting serotonin 5-HT2 receptor agonist with favorable PK and PD properties,” concluded Dr. Varty.
- Title: Synthesis and Structure-Activity Relationships of 2,5-dimethoxy-4-substituted phenethylamines and the discovery of CYB210010: A potent, orally bioavailable and long-acting serotonin 5-HT2 receptor agonist